サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：肝臓がんの世界市場 - 市場シェア・規模・動向・業界分析：タイプ別、治療タイプ別、地域別、セグメント予測（2022年～2030年）
市場調査レポート
商品コード
1150065

肝臓がんの世界市場 - 市場シェア・規模・動向・業界分析：タイプ別、治療タイプ別、地域別、セグメント予測（2022年～2030年）

Liver Cancer Market Share, Size, Trends, Industry Analysis Report, By Type (Cholangio Carcinoma, Hepatocellular Carcinoma, Hepatoblastoma, Others); By Treatment Type; By Region; Segment Forecast, 2022 - 2030
出版日: | 発行: Polaris Market Research | ページ情報: 英文 116 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
肝臓がんの世界市場 - 市場シェア・規模・動向・業界分析：タイプ別、治療タイプ別、地域別、セグメント予測（2022年～2030年）
出版日: 2022年10月01日
発行: Polaris Market Research
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の肝臓がんの市場規模は、2030年までに104億8,000万米ドルに達すると予測されています。

当レポートでは、世界の肝臓がん市場を調査しており、市場の概要、市場規模や予測、動向、促進要因・抑制要因、タイプ別・治療タイプ別・地域別などの分析、さらに企業プロファイルなどを提供しています。

目次

第1章 イントロダクション

  • レポートの説明
    • 調査の目的
    • 市場範囲
    • 前提条件
  • 利害関係者

第2章 エグゼクティブサマリー

  • 市場のハイライト

第3章 調査手法

  • 概要
    • データマイニング
  • 情報源
    • 一次情報
    • 二次情報

第4章 世界の肝臓がん市場の洞察

  • 肝臓がん市場 - 業界のスナップショット
  • 肝臓がん市場力学
    • 促進要因と機会
    • 抑制要因と課題
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 新規参入者の脅威
    • 買い手の交渉力
    • 代替品の脅威
    • 既存企業間の競争力
  • PESTLE分析
  • 肝臓がん業界の動向
  • バリューチェーン分析
  • COVID-19影響分析

第5章 世界の肝臓がん市場：タイプ別

  • 主な調査結果
  • イントロダクション
    • 世界の肝臓がん、タイプ別（2018年～2030年）
  • 肝細胞がん
    • 世界の肝臓がん市場、肝細胞がん別、地域別（2018年～2030年）
  • 胆管がん
    • 世界の肝臓がん市場、胆管がん別、地域別（2018年～2030年）
  • 肝芽腫
    • 世界の肝臓がん市場、肝芽腫別、地域別（2018年～2030年）
  • その他
    • 世界の肝臓がん市場、その他別、地域別（2018年～2030年）

第6章 世界の肝臓がん市場：治療タイプ別

  • 主な調査結果
  • イントロダクション
    • 世界の肝臓がん市場、治療タイプ別（2018年～2030年）
  • 標的薬物療法
    • 世界の肝臓がん市場、標的薬物療法別、地域別（2018年～2030年）
  • 免疫療法
    • 世界の肝臓がん市場、免疫療法別、地域別（2018年～2030年）
  • 化学療法
    • 世界の肝臓がん市場、化学療法別、地域別（2018年～2030年）

第7章 世界の肝臓がん市場：地域別

  • 主な調査結果
  • イントロダクション
    • 肝臓がん市場の評価、地域別（2018年～2030年）
  • 肝臓がん市場 - 北米
    • 北米：肝臓がん市場、治療タイプ別（2018年～2030年）
    • 北米：肝臓がん市場、タイプ別（2018年～2030年）
    • 肝臓がん市場 - 米国
    • 肝臓がん市場 - カナダ
  • 肝臓がん市場 - 欧州
    • 欧州：肝臓がん市場、治療タイプ別（2018年～2030年）
    • 欧州：肝臓がん市場、タイプ別（2018年～2030年）
    • 肝臓がん市場 - 英国
    • 肝臓がん市場 - フランス
    • 肝臓がん市場 - ドイツ
    • 肝臓がん市場 - イタリア
    • 肝臓がん市場 - スペイン
    • 肝臓がん市場 - オランダ
    • 肝臓がん市場 - ロシア
  • 肝臓がん市場 - アジア太平洋
    • アジア太平洋：肝臓がん市場、治療タイプ別（2018年～2030年）
    • アジア太平洋：肝臓がん市場、タイプ別（2018年～2030年）
    • 肝臓がん市場 - 中国
    • 肝臓がん市場 - インド
    • 肝臓がん市場 - マレーシア
    • 肝臓がん市場 - 日本
    • 肝臓がん市場 - インドネシア
    • 肝臓がん市場 - 韓国
  • 肝臓がん市場 - 中東・アフリカ
    • 中東・アフリカ：肝臓がん市場、治療タイプ別（2018年～2030年）
    • 中東・アフリカ：肝臓がん市場、タイプ別（2018年～2030年）
    • 肝臓がん市場 - サウジアラビア
    • 肝臓がん市場 - アラブ首長国連邦
    • 肝臓がん市場 - イスラエル
    • 肝臓がん市場 - 南アフリカ
  • 肝臓がん市場 - ラテンアメリカ
    • ラテンアメリカ：肝臓がん市場、治療タイプ別（2018年～2030年）
    • ラテンアメリカ：肝臓がん市場、タイプ別（2018年～2030年）
    • 肝臓がん市場 - メキシコ
    • 肝臓がん市場 - ブラジル
    • 肝臓がん市場 - アルゼンチン

第8章 競合情勢

  • 拡大・買収の分析
    • 拡大
    • 買収
  • パートナーシップ/コラボレーション/協定/公開

第9章 企業プロファイル

  • Abbott Laboratories
  • Roche
  • Bayer AG
  • Bristol Myers Squibb Company
  • Celsion Corporation
  • Eisai Co.
  • Exelixis
  • Eli Lilly
  • Qiagen N.V
  • Merck
  • Pfizer
  • AbbVie
  • Amgen
  • Thermo Fisher Scientific
  • AstraZeneca
  • Johnson & Johnson
  • Sanofi SA
  • Novartis AG
図表

List of Tables

  • Table 1 Global Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 2 Global Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 3 Liver Cancer Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • Table 4 North America: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 5 North America: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 6 U.S.: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 7 U.S.: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 8 Canada: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 9 Canada: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 10 Europe: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 11 Europe: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 12 UK: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 13 UK: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 14 France: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 15 France: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 16 Germany: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 17 Germany: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 18 Italy: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 19 Italy: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 20 Spain: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 21 Spain: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 22 Netherlands: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 23 Netherlands: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 24 Russia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 25 Russia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 26 Asia Pacific: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 27 Asia Pacific: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 28 China: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 29 China: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 30 India: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 31 India: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 32 Malaysia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 33 Malaysia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 34 Japan: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 35 Japan: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 36 Indonesia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 37 Indonesia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 38 South Korea: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 39 South Korea: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 40 Middle East & Africa: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 41 Middle East & Africa: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 42 Saudi Arabia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 43 Saudi Arabia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 44 UAE: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 45 UAE: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 46 Israel: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 47 Israel: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 48 South Africa: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 49 South Africa: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 50 Latin America: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 51 Latin America: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 52 Mexico: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 53 Mexico: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 54 Brazil: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 55 Brazil: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • Table 56 Argentina: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • Table 57 Argentina: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)

List of Figures

Figure 1 Global Liver Cancer Market, 2018 - 2030 (USD Billion)

Figure 2 Integrated Ecosystem

Figure 3 Research Methodology: Top-Down & Bottom-Up Approach

Figure 4 Market by Geography

Figure 5 Porter's Five Forces

Figure 6 Market by Treatment Type

Figure 7 Global Liver Cancer Market, by Treatment Type, 2021 & 2030 (USD Billion)

Figure 8 Market by Type

Figure 9 Global Liver Cancer Market, by Type, 2021 & 2030 (USD Billion)

Figure 10 Liver Cancer Market Assessment, By Geography, 2018 - 2030 (USD Billion)

Figure 11 Strategic Analysis - Liver Cancer Market

目次
Product Code: PM1342

The global liver cancer market size is expected to reach USD 10.48 billion by 2030, according to a new study by Polaris Market Research. The report "Liver Cancer Market Share, Size, Trends, Industry Analysis Report, By Type (Cholangio Carcinoma, Hepatocellular Carcinoma, Hepatoblastoma, Others); By Treatment Type; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The main drivers influencing the market growth are the rising incidence of liver cancer, increased investments in research & development to create novel medicines, and government programmers to raise cancer awareness. For instance, the Globocan 2020 study estimates that approximately 905,677 new cases of liver cancer were detected worldwide.

Moreover, according to Cancer Research UK, there are around 6,200 new liver cancer cases in the UK each year, or 17 cases every day. With 2% of all new cancer cases, liver cancer is the 18th most prevalent malignancy in the UK. Liver cancer is the 20th most prevalent cancer in women in the UK, with about 2,100 new cases per year.

Additionally, the market is anticipated to rise due to rising research initiatives and funding, which might lead to the developing of an innovative liver cancer treatment if these studies have successful outcomes. For instance, according to Clinical Trial.gov, NETRIS Pharma and University Hospital, Grenoble collaborated to study on September 23, 2022, will assess the safety of the association of NP137 with the standard of care Atezolizumab-Bevacizumab in the first-line setting in patients with unresectable hepatocellular carcinoma.

The NP137 study medication is being evaluated with atezolizumab-bevacizumab to improve tumor response and survival outcomes while maintaining acceptable safety. The trial officially began in November 2022 and is scheduled to end in November 2024.

Furthermore, a researcher from Australia's Edith Cowan University got USD 2.35 million in funding to support a new type of radiation treatment for liver cancer that will be trialed across Australia over the next five years. Due to the increasing prevalence of liver cancer and associated risk factors and continuous research and development efforts, the market is anticipated to rise rapidly throughout the forecast period.

But throughout the projection period, expansion in the market is anticipated to be constrained by elements including side effects linked to specific pharmaceuticals, the high price of cancer therapies, and strict regulatory environments.

Liver Cancer Market Report Highlights

In 2021, hepatocellular carcinoma is expected to rule the liver cancer market. Technological advancement, personalized medicine, and cost-effective treatment options are factors that are anticipated to boost the expansion of the global market for hepatocellular carcinoma treatments.

In 2021, the targeted medication therapy category will account for the greatest share of the market. Targeted therapy is proving to be a viable prospective treatment with promising therapeutic effects in a number of cancers.

In 2021, the North America accounted for the largest revenue share in 2021. The main factors influencing market expansion in North America are the rising incidence of liver cancer in the area, the presence of sizable market participants, and the development of novel products.

The global players with global presence include Abbott Laboratories, F. Hoffmann-La Roche, Bayer AG, Bristol Myers Squibb Company, and Celsion Corporation.

Polaris Market Research has segmented the Liver Cancer Market report based on, type, treatment type, and region:

Liver Cancer, Type Outlook (Revenue - USD Billion, 2018 - 2030)

Hepatocellular Carcinoma

Cholangio Carcinoma

Hepatoblastoma

Other Types

Liver Cancer, Treatment Type Outlook (Revenue - USD Billion, 2018 - 2030)

Targeted Drug Therapy

Immunotherapy

Chemotherapy

Liver Cancer, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Liver Cancer Market Insights

  • 4.1. Liver Cancer Market - Industry Snapshot
  • 4.2. Liver Cancer Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing prevalence of liver cancer
      • 4.2.1.2. Rising initiatives undertaken by public and private organizations
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of diagnostic imaging
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Liver Cancer Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Liver Cancer Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Liver Cancer, by Type, 2018 - 2030 (USD Billion)
  • 5.3. Hepatocellular Carcinoma
    • 5.3.1. Global Liver Cancer Market, by Hepatocellular Carcinoma, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Cholangio Carcinoma
    • 5.4.1. Global Liver Cancer Market, by Cholangio Carcinoma, by Region, 2018 - 2030 (USD Billion)
  • 5.5. Hepatoblastoma
    • 5.5.1. Global Liver Cancer Market, by Hepatoblastoma, by Region, 2018 - 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Global Liver Cancer Market, by Others, by Region, 2018 - 2030 (USD Billion)

6. Global Liver Cancer Market, by Treatment Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • 6.3. Targeted Drug Therapy
    • 6.3.1. Global Liver Cancer Market, by Targeted Drug Therapy, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Immunotherapy
    • 6.4.1. Global Liver Cancer Market, by Immunotherapy, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Chemotherapy
    • 6.5.1. Global Liver Cancer Market, by Chemotherapy, by Region, 2018 - 2030 (USD Billion)

7. Global Liver Cancer Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Liver Cancer Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 7.3. Liver Cancer Market - North America
    • 7.3.1. North America: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 7.3.2. North America: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.3.3. Liver Cancer Market - U.S.
      • 7.3.3.1. U.S.: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.3.3.2. U.S.: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.3.4. Liver Cancer Market - Canada
      • 7.3.4.1. Canada: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.3.4.2. Canada: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 7.4. Liver Cancer Market - Europe
    • 7.4.1. Europe: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 7.4.2. Europe: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.4.3. Liver Cancer Market - UK
      • 7.4.3.1. UK: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.4.3.2. UK: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.4.4. Liver Cancer Market - France
      • 7.4.4.1. France: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.4.4.2. France: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.4.5. Liver Cancer Market - Germany
      • 7.4.5.1. Germany: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.4.5.2. Germany: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.4.6. Liver Cancer Market - Italy
      • 7.4.6.1. Italy: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.4.6.2. Italy: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.4.7. Liver Cancer Market - Spain
      • 7.4.7.1. Spain: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.4.7.2. Spain: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.4.8. Liver Cancer Market - Netherlands
      • 7.4.8.1. Netherlands: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.4.8.2. Netherlands: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.4.9. Liver Cancer Market - Russia
      • 7.4.9.1. Russia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.4.9.2. Russia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 7.5. Liver Cancer Market - Asia Pacific
    • 7.5.1. Asia Pacific: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 7.5.2. Asia Pacific: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.5.3. Liver Cancer Market - China
      • 7.5.3.1. China: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.5.3.2. China: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.5.4. Liver Cancer Market - India
      • 7.5.4.1. India: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.5.4.2. India: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.5.5. Liver Cancer Market - Malaysia
      • 7.5.5.1. Malaysia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.5.5.2. Malaysia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.5.6. Liver Cancer Market - Japan
      • 7.5.6.1. Japan: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.5.6.2. Japan: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.5.7. Liver Cancer Market - Indonesia
      • 7.5.7.1. Indonesia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.5.7.2. Indonesia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.5.8. Liver Cancer Market - South Korea
      • 7.5.8.1. South Korea: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.5.8.2. South Korea: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 7.6. Liver Cancer Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 7.6.2. Middle East & Africa: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.6.3. Liver Cancer Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.6.4. Liver Cancer Market - UAE
      • 7.6.4.1. UAE: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.6.4.2. UAE: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.6.5. Liver Cancer Market - Israel
      • 7.6.5.1. Israel: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.6.5.2. Israel: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.6.6. Liver Cancer Market - South Africa
      • 7.6.6.1. South Africa: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.6.6.2. South Africa: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 7.7. Liver Cancer Market - Latin America
    • 7.7.1. Latin America: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 7.7.2. Latin America: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.7.3. Liver Cancer Market - Mexico
      • 7.7.3.1. Mexico: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.7.3.2. Mexico: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.7.4. Liver Cancer Market - Brazil
      • 7.7.4.1. Brazil: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.7.4.2. Brazil: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.7.5. Liver Cancer Market - Argentina
      • 7.7.5.1. Argentina: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.7.5.2. Argentina: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Abbott Laboratories
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Roche
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Bayer AG
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Bristol Myers Squibb Company
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Celsion Corporation
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Eisai Co.
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Exelixis
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Eli Lilly
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Qiagen N.V
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Merck
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Pfizer
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. AbbVie
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Amgen
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Thermo Fisher Scientific
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. AstraZeneca
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development
  • 9.16. Johnson & Johnson
    • 9.16.1. Company Overview
    • 9.16.2. Financial Performance
    • 9.16.3. Product Benchmarking
    • 9.16.4. Recent Development
  • 9.17. Sanofi SA
    • 9.17.1. Company Overview
    • 9.17.2. Financial Performance
    • 9.17.3. Product Benchmarking
    • 9.17.4. Recent Development
  • 9.18. Novartis AG
    • 9.18.1. Company Overview
    • 9.18.2. Financial Performance
    • 9.18.3. Product Benchmarking
    • 9.18.4. Recent Development